Roche: encouraging results for breast cancer

(CercleFinance.com) - Friday, Roche unveiled the first encouraging results of a phase-III study on giredestrant, an experimental oral pill for breast cancer.


After 14 days of treatment, the drug has shown a reduction of 80% of the Ki67 marker which measures the proliferation of tumours, compared to 67% for anastrozole, an anti-cancer treatment developed by AstraZeneca.

These results, obtained from patients with early-stage breast cancer with positive oestrogen and post-menopause receptors now need to be presented at the ESMO congress.

Since the end of 2020, giredestrant has been part of a fast-track approval procedure with the US FDA.

Copyright (c) 2021 CercleFinance.com. All rights reserved.